[{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Helix BioPharma"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"||IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Vetter Pharma-Fertigung GmbH & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Vetter Pharma-Fertigung GmbH & Co","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Vetter Pharma-Fertigung GmbH & Co"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"}]

Find Dermatology Drugs in Phase III Clinical Development in SWITZERLAND

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : M1095 (sonelokimab) is an investigational humanised Nanobody® targeting IL-17A and IL-17F, it is being evaluated for the treatment of moderate to severe hidradenitis suppurativa.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 16, 2024

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : QM1114-DP (relabotulinumtoxinA) is a botulinum toxin neuromodulator, which is under phase 3 clinical development for the treatment of glabellar frown lines & lateral canthal lines.

                          Product Name : Relfydess

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 16, 2024

                          Lead Product(s) : RelabotulinumtoxinA

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : QM1114-DP (RelabotulinumtoxinA) is a rapid and long lasting small molecule injection formulation, which is being investigated for dermatological conditions like Crow’s Feet and Frown Lines.

                          Product Name : Relfydess

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          November 30, 2023

                          Lead Product(s) : RelabotulinumtoxinA

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the agreement, Sandoz will support Samsung Bioepis pipeline expansion by commercialising SB17, a proposed biosimilar to Stelara (ustekinumab) strengthening its immunology portfolio in the US, Canada, European Economic Area, Switzerland and UK.

                          Product Name : SB17

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Samsung Bioepis

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis.

                          Product Name : Cosentyx

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 26, 2023

                          Lead Product(s) : Secukinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Through the spinoff, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).

                          Product Name : SB17

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 10, 2023

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Demerger

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Cosentyx (secukinumab) is the human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyl...

                          Product Name : Cosentyx

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 02, 2023

                          Lead Product(s) : Secukinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Through the divestment, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).

                          Product Name : SB17

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 10, 2023

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Demerger

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BotulinumtoxinA (RelabotulinumtoxinA) is designed as a liquid, avoiding the traditional requirement to reconstitute from powder, eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency ...

                          Product Name : Alluzience

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 06, 2022

                          Lead Product(s) : Botulinum Toxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms.

                          Product Name : Cosentyx

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 09, 2022

                          Lead Product(s) : Secukinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank